PolyPid Ltd (NAS:PYPD)
$ 3.55 0.15 (4.41%) Market Cap: 24.15 Mil Enterprise Value: 25.84 Mil PE Ratio: 0 PB Ratio: 10.63 GF Score: 37/100

PolyPid Ltd at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 09, 2021 / 12:30PM GMT
Release Date Price: $312.3 (+2.56%)
Dikla Czaczkes Akselbrad
PolyPid Ltd. - Executive VP & CFO

Balaji, we are live.

Balaji V. Prasad
Barclays Bank PLC, Research Division - Director

Thanks. Hi, good morning, everyone, and thank you for dialing into the Barclays Global Healthcare Conference, and this is same virtual one. So it's a pleasure to have PolyPidâs management kick start the specialty pharma track of our Global Healthcare Conference. And from PolyPid, we have Dikla Akselbrad, EVP and CFO.

With this we'll kickstart proceedings. The format will be around 10 minutes of presentation and 15 minutes of fireside Q&A. And with that, Dikla would like to start the presentation.

Dikla Czaczkes Akselbrad
PolyPid Ltd. - Executive VP & CFO

Thank you, Balaji, and good morning, everyone. Thank you for the opportunity to being in this track. Now the slide are on.

So PolyPid is a late-stage biopharmaceutical company, running now 2 Phase III, first one is going to read out by the end of this year with the aim to show superiority

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot